Global Neurology Academy
The Global Neurology Academy (GNA) series offers certified education modules and video interviews from leading MS experts from across the globe as they address topics such as induction therapy in relapsing-remitting multiple sclerosis; No Evidence of Disease Activity (NEDA) concept; how different agents used in MS management may be utilized in induction therapy; appreciation of how reductions in end-organ damage impact patient quality-of-life; mechanisms of action of the classical as well as emergent agents; key issues associated with making the correct differential diagnosis of multiple sclerosis, in addition to how best to incorporate prognostic indicators into clinical decision-making; current and emergent novel oral agents in MS management; and diagnostic strategies and identifying predictors of outcome.
For more information about GNA, visit www.globalneurologyacademy.org.
151-165 of 235
Managing MS in Older Adults: Key Considerations for DMTs and Lifestyle Interventions
On the Frontlines of Multiple SclerosisManaging MS in Older Adults: Key Considerations for DMTs and Lifestyle Interventions
Charles Turck, PharmD, BCPS, BCCCP
Kimberly DiMauro, DO
Carol Swetlik, MD
Optimizing Schizophrenia Care: Strategies for Managing Side Effects and Treatment Resistance
On the Frontlines of SchizophreniaOptimizing Schizophrenia Care: Strategies for Managing Side Effects and Treatment Resistance
Joseph F. Goldberg, MD
Understanding Schizophrenia: Early Intervention and Prevention Strategies
On the Frontlines of SchizophreniaUnderstanding Schizophrenia: Early Intervention and Prevention Strategies
Joseph F. Goldberg, MD
Reducing Cortical Lesions in MS with Ocrelizumab: Results from the ORATORI Study
NeuroFrontiersReducing Cortical Lesions in MS with Ocrelizumab: Results from the ORATORI Study
Michael G. Dwyer, PhD
Studying Cortical Lesions in MS: Future Research Directions
NeuroFrontiersStudying Cortical Lesions in MS: Future Research Directions
Michael G. Dwyer, PhD
Unraveling the Mechanism: How Ocrelizumab Impacts Cortical Lesions in MS
NeuroFrontiersUnraveling the Mechanism: How Ocrelizumab Impacts Cortical Lesions in MS
Michael G. Dwyer, PhD
- advertisement
mIDH Gliomas Explained: Characteristics and Management Strategies
NeuroFrontiersmIDH Gliomas Explained: Characteristics and Management Strategies
Jennie Taylor, MD
Vorasidenib and mIDH Gliomas: Reviewing the Efficacy Data
NeuroFrontiersVorasidenib and mIDH Gliomas: Reviewing the Efficacy Data
Jennie Taylor, MD
Climate Change in the Clinic: Examining Neurological Impacts
NeuroFrontiersClimate Change in the Clinic: Examining Neurological Impacts
Beth Ann Malow, MD, MS
Decoding CIDP: Pathogenesis, Diagnosis, and Clinical Clues
On the Frontlines of CIDPDecoding CIDP: Pathogenesis, Diagnosis, and Clinical Clues
Hans Katzberg, MD
Treatment Advances in Generalized Myasthenia Gravis: Clinical and Laboratory Criteria for Diagnosis and Optimal Treatment Selection
CME/CETreatment Advances in Generalized Myasthenia Gravis: Clinical and Laboratory Criteria for Diagnosis and Optimal Treatment Selection
Vera Bril, MD
Jonathan Strober, MD
Vera Bril, MD
Nicholas J. Silvestri, MD
Hans Katzberg, MD
- advertisement
Autoantibodies Explained: Anti-AChR, Anti-MuSK, and Their Diagnostic Role
MinuteCE®Autoantibodies Explained: Anti-AChR, Anti-MuSK, and Their Diagnostic Role
Vera Bril, MD
Nicholas J. Silvestri, MD
Evolving Strategies in CIDP Care: Personalized Approaches and Emerging Treatments
On the Frontlines of CIDPEvolving Strategies in CIDP Care: Personalized Approaches and Emerging Treatments
Sami Khella, MD
Understanding CIDP: A Roadmap to Diagnosis
On the Frontlines of CIDPUnderstanding CIDP: A Roadmap to Diagnosis
Sami Khella, MD
